Summary
Becton Dickinson & Co. (BDX) filed its 2009 10-K report on November 24, 2009, covering the fiscal year ended September 29, 2009. This filing provides a comprehensive overview of the company's business, financial performance, and strategic outlook. Investors can gain insights into the company's operations across its key segments, which typically include medical, diagnostic, and surgical products, by reviewing the "Business" section. The "Management's Discussion and Analysis of Financial Condition and Results of Operations" is crucial for understanding the drivers of revenue and profitability, as well as the company's liquidity and capital resources.
Financial Highlights
55 data pointsBeta
Financial Statements
Beta
| Revenue | $6.99B |
| Cost of Revenue | $3.31B |
| Gross Profit | $3.68B |
| R&D Expenses | $404.57M |
| SG&A Expenses | $1.68B |
| Operating Expenses | $5.40B |
| Operating Income | $1.59B |
| Interest Expense | $40.39M |
| Net Income | $1.23B |
| EPS (Basic) | $5.12 |
| EPS (Diluted) | $4.99 |
| Shares Outstanding (Basic) | 240.48M |
| Shares Outstanding (Diluted) | 246.80M |
Key Highlights
- 1The 10-K report details Becton Dickinson's business operations, encompassing its various product segments and global reach.
- 2Key financial data and trends for the fiscal year ending September 29, 2009, are presented, offering insights into revenue, profitability, and expense management.
- 3The Management's Discussion and Analysis (MD&A) section is vital for understanding the company's financial condition, including its liquidity, capital resources, and the factors influencing its results of operations.
- 4Risk factors are outlined, providing investors with potential challenges and uncertainties that could impact the company's future performance.
- 5Information on legal proceedings, properties, and corporate governance practices is included, offering a broader view of the company's operational and structural aspects.
- 6Details on market risks and quantitative disclosures related to market risk exposures are provided, allowing investors to assess the company's sensitivity to market fluctuations.
Frequently Asked Questions
While the 10-K filing provides detailed information, Becton Dickinson's business historically has been organized into segments such as Medical, which includes medication management and safety solutions; Diagnostic, focused on specimen collection and diagnostic instrument systems; and International operations.
The report would typically detail revenue growth, gross profit margins, operating income, net income, and earnings per share for the fiscal year. Investors should pay close attention to the trends in these metrics and the narrative provided in the MD&A section to understand the underlying reasons for performance.
Common risks for companies like Becton Dickinson in this period could include regulatory changes, competition, product recalls, economic downturns affecting healthcare spending, currency fluctuations, and integration risks from acquisitions. The specific risks detailed in Item 1A of the filing are essential for a complete understanding.
The MD&A section (Item 7) would discuss the company's cash flows, debt levels, access to credit facilities, and its strategies for managing working capital. Investors should look for information regarding the company's ability to fund its operations, capital expenditures, and any potential impact from prevailing economic conditions.